ArticleDocumenta ophthalmologica. Advances in ophthalmology2017
Unilateral cancer-associated retinopathy: diagnosis, serology and treatment.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Electronegative ERG in association with probable TRPM1-related cancer associated retinopathy: a case report.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- Diagnosis and treatment of autoimmune retinopathy: review of current approaches.International ophthalmology · 2025Review
- Article
- Intravenous rituximab and oral cyclophosphamide for the treatment of cancer‑associated retinopathy in a patient with epithelial ovarian cancer: A case report.Oncology letters · 2023Article
- Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.Documenta ophthalmologica. Advances in ophthalmology · 2022Article
- Paraneoplastic syndrome in neuroophthalmology.Journal of neurology · 2022Review
- Primary ovarian adenocarcinoma presenting with rubeotic glaucoma and vitritis: A case report.Clinical case reports · 2022Article
- Autoimmune Retinopathy, Testing, and Its Controversies.Current ophthalmology reports · 2021Article
- Negative electroretinograms: genetic and acquired causes, diagnostic approaches and physiological insights.Eye (London, England) · 2021Review
- Unilaterally extinguished electroretinograms in an eye with normal visual acuity and visual field.Documenta ophthalmologica. Advances in ophthalmology · 2021Observational
- Prevalence of electronegative electroretinograms in a healthy adult cohort.BMJ open ophthalmology · 2021Article
- Ocular Paraneoplastic Syndromes.Biomedicines · 2020Review
- An update on autoimmune retinopathy.Indian journal of ophthalmology · 2020Review
- Correlation of Immunological Markers with Disease and Clinical Outcome Measures in Patients with Autoimmune Retinopathy.Translational vision science & technology · 2020Article
- Non-paraneoplastic autoimmune retinopathy that developed in fellow eye 10 years after onset in first eye: a case report.BMC ophthalmology · 2020Article
- Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.PloS one · 2020Article
- Two cases of unilateral cone-rod dysfunction with negative electroretinograms.Documenta ophthalmologica. Advances in ophthalmology · 2019Article
- TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.Investigative ophthalmology & visual science · 2019Article
- Non-paraneoplastic autoimmune retinopathy: multimodal testing characteristics of 13 cases.Journal of ophthalmic inflammation and infection · 2019Article
- Unilateral paraneoplastic optic disc edema and retinal periphlebitis in pineal germinoma.American journal of ophthalmology case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report a case of unilateral cancer-associated retinopathy (CAR) with clinical, serological and electroretinogram (ERG) normalization after aggressive cancer treatment combined with steroids and rituximab.
methodsWork-up included extensive clinical and electrophysiological testing. Also, serological work-up for antiretinal antibodies and oncological screening was organized.
resultsA 45-year-old female presented with progressive photopsias, photophobia and relative central scotoma in the right eye since 6 weeks prior. BCVA was 1.0 in both eyes. Biomicroscopy, IOP and fundus exam were unremarkable. Also, colour vision, autofluorescence imaging, OCT and EOG were normal. Visual fields showed decreased central sensitivity in the right eye. ERG showed a unilateral, electronegative combined and ON-bipolar response. A diagnosis of CAR was suspected. After a diagnosis of an adenocarcinoma of the right ovary, radical ovariectomy and hysterectomy were performed, followed by adjuvant chemotherapy. A whole-body PET scan revealed no metastasis. Treatment with rituximab monoclonal antibodies in combination with corticosteroids was initiated. The patient tested positive for serum autoantibodies against TRPM1, a transient receptor potential cation channel expressed in ON-bipolar cells. During treatment, there was progressive improvement in symptoms and the ERG normalized. Serology confirmed complete clearance of autoantibodies.
conclusionsAlthough rare, unilateral CAR does occur and in cases with high clinical suspicion an oncological work-up is mandatory. Aggressive cancer treatment combined with steroids and rituximab can lead to normalization of the clinical and ERG phenotype, with clearing of antiretinal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.